Literature DB >> 2404871

Characterization of anti-core glycolipid monoclonal antibodies with chemically defined lipopolysaccharides.

J de Jongh-Leuvenink1, J Schellekens, J Verhoef.   

Abstract

Five anti-core glycolipid monoclonal antibodies (MAb) (four against Escherichia coli J5 lipopolysaccharide [LPS] and one against the Re core glycolipid of Salmonella typhimurium) were characterized using LPS from several rough and smooth strains and derivatives of E. coli J5 LPS, obtained by N acetylation and hydrolysis. The MAb against E. coli J5 were not only weakly cross-reactive with clinical isolates, whereas the anti-Re MAb was highly cross-reactive. The MAb differed in their reaction pattern with E. coli J5 LPS. MAb 4-7B5 (immunoglobulin M) and MAb 4-6A1 (immunoglobulin G1) cross-reacted with LPS of Salmonella minnesota R5 and S. typhimurium Ra and Rc and little with Re and lipid A. The dominant binding site of these MAb was located in the glucose-heptose-heptose region and was independent of phosphate substitution. The MAb 4-9A1 reacted with the terminal part of the core region (glucose-heptose) and was dependent on phosphate substitution of the LPS. The MAb BA7 (immunoglobulin G3) was E. coli J5 LPS specific and reacted with the glucosaminyl-heptose disaccharide. Antibody 8-2C1 was directed against the common parts of LPS, 3-deoxy-D-manno-octulosonic acid, and lipid A, which are not (or only weakly) recognized by the four anti-J5 LPS MAb. Thus, MAb that are not cross-reactive can be directed against at least three different antigenic determinants present on the core oligosaccharide of E. coli J5 LPS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2404871      PMCID: PMC258473          DOI: 10.1128/iai.58.2.421-426.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Failure of monoclonal antibodies to core glycolipid to bind intact smooth strains of Escherichia coli.

Authors:  F Gigliotti; J L Shenep
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

2.  Cross-reactivity of monoclonal antibodies against lipopolysaccharides of gram-negative bacteria.

Authors:  J de Jongh-Leuvenink; A S Bouter; J H Marcelis; J Schellekens; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

3.  Monoclonal antibodies specific for Escherichia coli J5 lipopolysaccharide: cross-reaction with other gram-negative bacterial species.

Authors:  L M Mutharia; G Crockford; W C Bogard; R E Hancock
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

4.  Characterization of murine monoclonal antibodies to Escherichia coli J5.

Authors:  K M Miner; C L Manyak; E Williams; J Jackson; M Jewell; M T Gammon; C Ehrenfreund; E Hayes; L T Callahan; H Zweerink
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

5.  Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies.

Authors:  N N Teng; H S Kaplan; J M Hebert; C Moore; H Douglas; A Wunderlich; A I Braude
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

6.  A method to detect 2-keto-3-deoxyoctanat and related compounds on pherograms and chromatograms.

Authors:  H Brade; C Galanos
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

7.  Structural investigations on the inner core region of lipopolysaccharides from Salmonella minnesota rough mutants.

Authors:  H Brade; H Moll; E T Rietschel
Journal:  Biomed Mass Spectrom       Date:  1985-10

8.  Cross-reactive immunoprotective antibodies to Escherichia coli O111 rough mutant J5.

Authors:  R Sakulramrung; G J Domingue
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

9.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.

Authors:  E J Ziegler; J A McCutchan; J Fierer; M P Glauser; J C Sadoff; H Douglas; A I Braude
Journal:  N Engl J Med       Date:  1982-11-11       Impact factor: 91.245

10.  Mouse monoclonal antibodies reactive with J5 lipopolysaccharide exhibit extensive serological cross-reactivity with a variety of gram-negative bacteria.

Authors:  M J Nelles; C A Niswander
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

View more
  4 in total

Review 1.  Infectious disease therapy in the 1990s. Where are we heading?

Authors:  M Rozenberg-Arska; M R Visser
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 2.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

3.  Influence of polyclonal immunoglobulins on the polymorphonuclear leukocyte response to lipopolysaccharide of Salmonella enteritidis as measured with luminol-enhanced chemiluminescence.

Authors:  D R Wagner; D Heinrich
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

4.  Development, characterization, and biological properties of meningococcal immunotype L3,7,(8),9-specific monoclonal antibodies.

Authors:  A F Verheul; A J Kuipers; A K Braat; H A Dekker; C C Peeters; H Snippe; J T Poolman
Journal:  Clin Diagn Lab Immunol       Date:  1994-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.